MISSION VIEJO, Calif., Sept. 07, 2017 (GLOBE NEWSWIRE) -- MYnd Analytics, Inc. (NASDAQ:MYND), a predictive medicine company which brings objective physical findings to psychiatric treatment in order to reduce trial and error prescribing in mental health, announces that CEO George Carpenter has been invited to present at the Brain Futures 2017 conference. The conference is being held from September 6-7th, 2017 at the Gaylord National Resort in Washington, D.C.
MYnd Analytics CEO George Carpenter will present at 12:50 PM Eastern Time on September 7th, in a session entitled, “From Pharmacogenetics to Psychedelics: Promising Medication Advances.” The session will explore the promise of personalized medicine in reducing trial and error prescribing for the treatment of mental health conditions by combining neuroimaging and genomics.
George Carpenter, CEO of MYnd Analytics, commented, “We are pleased to present at the Brain Futures 2017 Conference, which hosts many of the top mental health professionals from across the country. The session will include a detailed discussion of our ability to increase predictive accuracy of medications through machine learning to assist practitioners in properly treating behavioral health disorders and reducing costs associated with improper treatment. We also plan to discuss new pharmacogenomic variables we are adding to our core data, as well as expansion of our intellectual property portfolio.”
About Brain Futures
Brain Futures is increasing the range of therapeutic options available to the public by bridging the gap between research, innovation and practice and by providing rigorous and unbiased information about advances in brain health and cutting-edge care that is transforming patient outcomes.
About MYnd Analytics
MYnd Analytics, Inc. (www.myndanalytics.com) provides a unique set of reference data and analytic tools for clinicians and researchers in psychiatry. While treatment for mental disorders has doubled in the last 20 years, it is estimated that millions Americans have failed two or more medication therapies for their mental disorders. MYnd Analytics' Psychiatric EEG Evaluation Registry, or PEER Online®, is a registry and reporting platform that allows medical professionals to exchange treatment outcome data for patients referenced to objective neurophysiology data obtained through a standard electroencephalogram (EEG). Based on MYnd Analytics' original physician-developed database, there are now more than 38,000 outcomes for over 10,000 unique patients in the PEER registry. The goal of PEER Online® is to provide objective, personalized data to assist physicians in the selection of appropriate medications.
To read more about the benefits of this patented technology for patients, physicians and payers, please visit www.myndanalytics.com.